Strategy for encoding and comparison of gene expression signatures by Yi, Yajun et al.
Genome Biology 2007, 8:R133
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Open Access 2007 Yi et al. Volume 8, Issue 7, Article R133 Software
Strategy for encoding and comparison of gene expression 
signatures
Yajun Yi*, Chun Li†, Clay Miller* and Alfred L George Jr*‡
Addresses: *Department of Medicine, Garland Avenue, Vanderbilt University, Nashville, Tennessee 37232-0275,USA. †Department of 
Biostatistics, Garland Avenue, Vanderbilt University, Nashville, Tennessee 37232-0275,USA. ‡Department of Pharmacology, Garland Avenue, 
Vanderbilt University, Nashville, Tennessee 37232-0275,USA. 
Correspondence: Alfred L George. Email: al.george@Vanderbilt.Edu
© 2007 Yi et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comparison of expression signatures <p>EXALT (EXpression signature AnaLysis Tool) enables comparisons of microarray data across experimental platforms and different  laboratories.</p>
Abstract
EXALT (EXpression signature AnaLysis Tool) is a computational system enabling comparisons of
microarray data across experimental platforms and different laboratories http://
seq.mc.vanderbilt.edu/exalt/. An essential feature of EXALT is a database holding thousands of gene
expression signatures extracted from the Gene Expression Omnibus, and encoded in a searchable
format. This novel approach to performing global comparisons of shared microarray data may have
enormous value when coupled directly with a shared data repository.
Rationale
The application of high-throughput microarray technology
for determining global changes in gene expression is an
important and revolutionary experimental paradigm that
facilitates advances in functional genomics and systems biol-
ogy. Widespread use of this approach is evident in the rapid
growth of microarray datasets stored in public repositories
[1,2]. For example, the Gene Expression Omnibus (GEO),
curated by the National Center for Biotechnology Informa-
tion (NCBI), has received thousands of data submissions rep-
resenting more than 3 billion individual molecular
abundance measurements [3,4].
The growth in microarray data deposition is reminiscent of
the early days of GenBank, when exponential increases in
publicly accessible nucleotide sequence data occurred. How-
ever, unlike nucleotide sequences, microarray datasets are
not as easily shared by the research community, resulting in
many investigators being unable to exploit the full potential
of these data. New paradigms for searching and comparing
publicly available microarray results are needed to promote
widespread, investigator-driven research on shared data.
To meet this need, we developed and implemented a bioinfor-
matic strategy, termed EXALT (EXpression signature AnaLy-
sis Tool), to enable comparisons of microarray data across
experimental platforms, different laboratories, and multiple
species. Our system allows investigators to use gene expres-
sion signatures (also referred to as gene sets) to query a large
formatted collection of microarray results. We accomplished
this by first transforming a large collection of gene expression
data into a rank ordered format of differentially expressed
gene signatures within each experiment. Our strategy avoids
the difficulties encountered in direct comparisons of raw
microarray observations, and it is not hampered by different
experimental platforms. This new approach to mining shared
microarray data may have greatest value when it is offered as
an online tool for mining data in a repository such as GEO.
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Encoding gene expression signatures
In developing EXALT, we embraced the philosophy that
direct comparisons of raw microarray data would be neither
feasible nor beneficial. Rather than compare raw data, we
chose to implement a search paradigm that matches gene
expression signatures deduced from pre-processed (normal-
ized, background subtracted) data, such as that deposited in
the GEO database. Because of this feature, EXALT can com-
pare data from any microarray platform and is not dependent
on the methods used for the initial data processing. The out-
put from EXALT provides similarity scores and statistical
confidence levels for each signature match, thus allowing
rapid perusal of relationships between the query data and
entries in a database of other microarray experiments.
In order to create a searchable database, we first developed a
data structure to encode gene expression signatures that
incorporates three attributes, organized into 'triplets', of
genes exhibiting significant differences in expression. Each
triplet consists of an individual gene identifier, a statistical
score, and a direction code indicating whether the gene is
expressed at a higher (U for 'upregulated') or lower (D for
'downregulated') level between control and experimental
groups. Thus, a gene expression signature, as defined by
EXALT, is a set of significant genes with their corresponding
statistical scores and direction codes. In essence, a signature
(or group of signatures) represents a statistically validated
'fingerprint' associated with a biologic observation made from
a gene expression experiment.
A computational pipeline (array expression signature pipe-
line [AESP]) was implemented to convert automatically
microarray data from GEO and other sources into an encoded
gene expression signature database (SigDB). For this data-
base, each microarray study was partitioned into three levels:
datasets, groups, and samples. EXALT required that each
microarray study had one to many datasets based on its
experimental design, and that each dataset included at least
two groups. In each group, EXALT further required at least
two samples to serve as biologic replicates. Each sample
described the abundance measurements for each feature ele-
ment obtained from a single hybridization or experimental
condition. Two or more groups were needed to generate sta-
tistical comparisons. Significant genes were defined from two
groups of samples by calculating a Student's t-statistic, signif-
icant gene P value (false positive rate), and Q value (false dis-
covery rate). Correspondingly, gene expression signatures are
collections of significant genes determined from statistical
comparisons of groups. Because a microarray study can pro-
duce one or many gene expression signatures, depending on
the number of groups, we related the maximum total number
of signatures (TNS) to the group number (N) in the following
equation: TNS = (N × [N - 1])/2.
Among 874 GEO datasets representing microarray experi-
ments performed using human, mouse, or rat tissues, 620
(75%) were successfully converted into gene expression sig-
natures. The extracted signatures (total 16,181; average 1,683
significant genes per signature) from 14,303 hybridizations
populated three separate SigDB files for human, mouse, and
rat. The signatures in SigDB are designated as subject signa-
tures. Most datasets were either single-channel intensity
data, usually corresponding to Affymetrix microarrays, or
dual-channel ratio data, usually corresponding to spotted
cDNA microarrays. Additional SigDB entries originated from
published microarray studies that were not deposited in GEO,
as described in the Materials and methods section (below).
Design and validation of EXALT
The EXALT system consists of four components (two pro-
gram pipelines, SigDB, and search engine) and a web inter-
face (Figure 1). To compare a user-defined query with SigDB,
gene expression signatures were first extracted from a pre-
processed query data set using AESP. Each user-defined
query signature was then compared with every subject signa-
ture in SigDB by computing similarity scores and confidence
levels. Thus, all signatures from the query dataset were com-
pared with all signatures in SigDB. The EXALT comparisons
were based on estimating the degree of signature similarity
expressed as a normalized total identity score (TIS) between
expression signatures derived from a query dataset and sig-
natures in SigDB (see Materials and methods, below). The
significance of the similarity was determined by a simulation
analysis (see Materials and methods, below). Finally, reports
of similarity were summarized at three levels (gene, signa-
ture, and dataset) and sent to the user via an HTML report
pipeline (HRP). All results presented here were summarized
from dataset-level reports, and the confidence levels are
expressed as adjusted mean P  values (see Materials and
methods, below).
As a prerequisite for using EXALT, a user-defined, pre-proc-
essed query dataset must be in a simple table format or the
GEO simple omnibus format in text (SOFT) format. Then, the
user can upload the pre-processed microarray dataset to the
EXALT web server [5] by selecting the choice 'Uploading a
query dataset' in the top menu bar and obtaining a unique
dataset tracking identifier (ID). The EXALT server currently
runs query datasets in a batch mode. When analysis is com-
plete, the user can retrieve the EXALT result using the track-
ing ID. Other features such as searching and browsing
signatures from the EXALT databases are under
development.
To validate EXALT, we first tested whether the system could
correctly identify microarray datasets through signatures that
pre-existed in SigDB. We converted 124 randomly selected
GEO datasets (GDSs) with AESP and used these to query
SigDB. The number of signatures varied from 1 to 777 for
these datasets. All 'hits' in the database were ordered by
adjusted mean P value and the percentage of matching queryhttp://genomebiology.com/2007/8/7/R133 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. R133.3
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signatures. Results from this analysis demonstrated that the
top 'hits' for each GDS, as defined by lowest adjusted mean P
value and greatest percentage of matching query signatures,
were perfectly concordant with the corresponding entries in
SigDB. Twenty representative matching records are pre-
sented in Table 1. These results demonstrated that EXALT
was able to identify datasets correctly through comparisons
between query and subject signatures.
Relationship of statistical with biologic 
significance
We next considered whether the output of EXALT could be
used to judge the degree of biological relatedness between
query and subject datasets. In Figure 2, we plotted the trend
in adjusted mean P value for the top ten matches for six of the
data queries derived from the 124 self-matching results. In
each case, the first indexed 'hit' (match number 1)
Schematic representation of EXALT system Figure 1
Schematic representation of EXALT system. A data flow diagram of computational steps is shown on the left, illustrating input of subject (Gene Expression 
Omnibus [GEO] dataset [GDS]) and query datasets, extraction of gene expression signatures, comparison with signature database, and generation of 
reports. Representative EXALT outputs are illustrated on the right, with three report levels including gene alignment, signature matches, and dataset 
matches. Reports are coded in HTML and include hypertext links (underlined blue text) to publicly accessible data sources or to other report levels. Some 
special terms were used in the gene alignment report. 'Total score' is the sum of positive identity score (PIS) and negative identity score (NIS). 
'Concordance Identity Avg' is the average PIS per signature gene. 'Discordance Identity Avg' is the average NIS per signature gene. 'Concordant Similarity' 
is the number of concordant genes expressed as a percentage of the total number of genes in the signature. 'Discordant Similarity' is the number of 
discordant genes expressed as a percentage of the total number of genes in the signature. 'Alignment' refers to the list of query and matched subject 
triplets. AESP, array expression signature pipeline; EXALT, EXpression signature AnaLysis Tool; SigDB, signature database.
Query
Search
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Report generator
Signature database
(SigDB)
Signature extractor (AESP)
upload
query
GEO
GDS
EXALT Dataset Match Report
The Dataset QUERY = NCBI_Geo_GDS318 has 6 signatures
Matched Subject Datasets
GDS318 NCBI_Geo_GDS318 has 6 hit(s) (100%) with Average pValue=1.799e-06
GDS319 NCBI_Geo_GDS319 has 6 hit(s) (100%) with Average pValue=6.222e-06
GDS295 NCBI_Geo_GDS295 has 6 hit(s) (100%) with Average pValue=6.297e-06
GDS294 NCBI_Geo_GDS294 has 6 hit(s) (100%) with Average pValue=8.809e-06
GDS320 NCBI_Geo_GDS320 has 6 hit(s) (100%) with Average pValue=1.004e-05
GDS306 NCBI_Geo_GDS306 has 6 hit(s) (100%) with Average pValue=1.045e-05
GDS322 NCBI_Geo_GDS322 has 6 hit(s) (100%) with Average pValue=1.090e-05
GDS323 NCBI_Geo_GDS323 has 6 hit(s) (100%) with Average pValue=1.402e-05
GDS305 NCBI_Geo_GDS305 has 6 hit(s) (100%) with Average pValue=3.936e-05
GDS298 NCBI_Geo_GDS298 has 6 hit(s) (100%) with Average pValue=4.370e-05
GDS658 NCBI_Geo_GDS658 has 5 hit(s) (83%) with Average pValue=0.00552
GDS405 NCBI_Geo_GDS405 has 5 hit(s) (83%) with Average pValue=0.00662
GDS952 NCBI_Geo_GDS952 has 5 hit(s) (83%) with Average pValue=0.00869
GDS55 NCBI_Geo_GDS55   has 4 hit(s) (66%) with Average pValue=0.01087
GDS200 NCBI_Geo_GDS200 has 1 hit(s) (16%) with Average pValue=0.01151
GDS887 NCBI_Geo_GDS887 has 2 hit(s) (33%) with Average pValue=0.01294
GDS580 NCBI_Geo_GDS580 has 3 hit(s) (50%) with Average pValue=0.01658
GDS182 NCBI_Geo_GDS182 has 1 hit(s) (16%) with Average pValue=0.02979
GDS237 NCBI_Geo_GDS237 has 1 hit(s) (16%) with Average pValue=0.03610
EXALT Signaure Match Report
QUERY = NCBI_Geo_GDS318_ce1(GSM5755,GSM5756,GSM5757)_ce2(GSM5758,GSM5759,GSM5760)
(333 SigGenes)
Database = SigDB(3705 signatures)
DatasetMatch List
NCBI_Geo_GDS40 with 32 hits (9.75%)
NCBI_Geo_GDS41 with 29 hits (8.84%)
NCBI_Geo_GDS970 with 16 hits (4.87%)
NCBI_Geo_GDS233 with 13 hits (3.96%)
NCBI_Geo_GDS323 with 12 hits (3.65%)
NCBI_Geo_GDS297 with 8 hits (2.43%)
NCBI_Geo_GDS303 with 7 hits (2.13%)
NCBI_Geo_GDS321 with 7 hits (2.13%)
NCBI_Geo_GDS42 with 7 hits (2.13%)
NCBI_Geo_GDS13 with 6 hits (1.82%)
The Top Hit Per GDS Group
NCBI_Geo_GDS318_ce1(GSM5755,GSM5756,GSM5757,)_ce2(GSM5758,GSM5759,GSM5760,) pValue=1.349e-06
NCBI_Geo_GDS319_ce3(GSM5773,GSM5774,GSM5775,)_ce4(GSM5776,GSM5777,GSM5778,) pValue=5.398e-06
NCBI_Geo_GDS295_ce1(GSM5474,GSM5475,GSM5476,)_ce2(GSM5477,GSM5478,GSM5479,) pValue=6.522e-06
NCBI_Geo_GDS294_ce1(GSM5463,GSM5464,GSM5465,)_ce2(GSM5466,GSM5467,GSM5468,) pValue=6.522e-06
NCBI_Geo_GDS322_ce1(GSM5800,GSM5801,GSM5802,)_ce3(GSM5806,GSM5807,GSM5808,) pValue=1.252e-05
NCBI_Geo_GDS320_ce2(GSM5782,GSM5783,GSM5784,)_ce3(GSM5785,GSM5786,GSM5787,) pValue=2.135e-05
NCBI_Geo_GDS306_ce1(GSM5614,GSM5615,GSM5616,)_ce3(GSM5620,GSM5621,GSM5622,) pValue=3.161e-05
EXALT Gene Alignment Report
QUERY = NCBI_Geo_GDS318_ce1(GSM5755,GSM5756,GSM5757)_ce2(GSM5758,GSM5759,GSM5760)
(333 SigGenes)
Database = SigDB(3705 signatures)
>NCBI_Geo_GDS318_ce1(GSM5755,GSM5756,GSM5757)_ce2(GSM5758,GSM5759,GSM5760)
Length=333
total score=22377.60,positive identity score(PIS)=22377.60,negative identity score (NIS)=0,
Concordance Identity Avg =33.60,Discordance Identity Avg =0
Total Identity Score (TIS)=33.6,Zscore=137.188715325827,pValue=1.34952766531714e-06
Match Ucount=0, Dcount=333,
Unmatch Ucount=0, Dcount=0, Ncount=0
Questionable match Qcount=0
Concordant Similarity=100%, Discordant Similarity=0%
qValue=0.000423751686909582
ALIGNMENT
Query : Subject
NM_001006668-D-33.60 : NM_001006668-D-33.60 : 67.2
NM_007376-D-33.60 : NM_007376-D-33.60 : 67.2R133.4 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. http://genomebiology.com/2007/8/7/R133
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represented a self-match and the other nine were matches
with subject datasets having varying levels of similarity.
The variation in adjusted mean P value trends among the
query datasets illustrated in Figure 2 may potentially repre-
sent different biologic relationships between the query and
the subject datasets. To explore this idea further, we exam-
ined the dataset matches for two specific queries (GDS318
and GDS607) that exhibited marked differences in P value
trends. For the query GDS318, all ten top 'hits' had adjusted
mean P values similar to the self-match (P < 1.55 × 10-05). By
contrast, adjusted mean P values for subject datasets match-
ing query GDS607 increased steadily through the progression
of ordered hits. To determine whether these different
adjusted mean P value trends reflect different biologic rela-
tionships, we explored the annotations for each matching
dataset. Matches to GDS318 belong to the same cluster of
datasets (anchored by GDS318 set) from a single microarray
study [6]. The goal of that study was to examine time-depend-
ent changes in gene expression for mouse splenic B lym-
phocytes stimulated with 33 different ligands known to
directly induce or co-stimulate proliferation. The specific lig-
and used in generating GDS318 was stromal cell derived fac-
tor-1, whereas the ligands studied in the matching subject
datasets were secondary lymphoid-organ chemokine, bombe-
sin, B-lymphocyte chemoattractant, terbutaline, insulin-like
growth factor-1, tumor necrosis factor-α, 2-methyl-thio-ATP,
and sphingosine-1-phosphate. All of these ligands induce
similar physiologic events, including B-cell migration and
homing [7,8], lymphocyte trafficking [9,10], and mitogenic
activation [11]. These results indicate that EXALT can define
related gene expression signatures evoked by a heterogenous
group of ligands.
By contrast, the annotations for datasets matching GDS607
reflect greater biologic heterogeneity. The GDS607 dataset
originated from a study of mouse spermatogenesis and testis
development, and nearly half (four out of nine) of the match-
ing subject datasets are biologically related. For example,
GDS662, GDS704, GDS606, and GDS660 refer to studies of
spermatogenesis and embryonic testis. However, the biologic
relationships of GDS607 to the remaining five matching data-
sets are less clear: GDS900 (kidney inner medulla from
aquaporin-1 null and wild-type mice), GDS604 (neurofi-
bromatosis and neurodevelopment), GDS592 (expression
profiles from 61 physiologically normal tissues), GDS14 (lung
responses to allergic stimuli), and GDS61 (vascular remode-
ling in pulmonary hypertension). We interpret these findings
as an illustration that the level of statistical significance
defined by EXALT correlates generally with biologic
Table 1
Self-matching test results for datasets compared using EXALT
Query dataset Number of query 
signatures
'Top hit' dataset Number of 'top hit' 
signatures (% of query)
P valuea
GDS1011 4 GDS1011 4 (100%) 1.08 × 10-06
GDS1023 7 GDS1023 7 (100%) 3.00 × 10-06
GDS1030 6 GDS1030 6 (100%) 2.84 × 10-06
GDS1048 103 GDS1048 103 (100%) 2.84 × 10-07
GDS422 65 GDS422 65 (100%) 2.03 × 10-07
GDS430 6 GDS430 6 (100%) 5.55 × 10-07
GDS44 10 GDS44 10 (100%) 1.17 × 10-07
GDS592 777 GDS592 777 (100%) 1.08 × 10-06
GDS666 5 GDS666 5 (100%) 6.84 × 10-07
GDS690 2 GDS690 2 (100%) 6.48 × 10-07
GDS700 2 GDS700 2 (100%) 1.06 × 10-06
GDS711 15 GDS711 15 (100%) 1.45 × 10-07
GDS264 6 GDS264 6 (100%) 2.94 × 10-08
GDS279 2 GDS279 2 (100%) 1.84 × 10-06
GDS286 14 GDS286 14 (100%) 1.04 × 10-06
GDS292 6 GDS292 6 (100%) 1.17 × 10-05
GDS948 6 GDS948 6 (100%) 8.28 × 10-06
GDS955 14 GDS955 14 (100%) 2.51 × 10-06
GDS958 2 GDS958 2 (100%) 2.56 × 10-05
GDS961 1 GDS961 1 (100%) 2.65 × 10-07
aAdjusted mean P value of all matching datasets. GDS, Gene Expression Omnibus dataset. EXALT, EXpression signature AnaLysis Tool.http://genomebiology.com/2007/8/7/R133 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. R133.5
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relatedness among experiments. However, these results may
also be informative as to less obvious relationships that will
require additional investigations to be fully revealed.
Cross-platform comparisons of expression 
signatures
We next tested whether EXALT could identify related gene
expression signatures in biologically related datasets gener-
ated using different microarray platforms. For this test we
utilized publicly available expression data generated from the
NCI-60 panel of cancer cell lines by three independent labo-
ratories [12-14] using either oligonucleotide (Affymetrix) or
spotted cDNA arrays. Previously, Kuo and coworkers [15]
demonstrated that comparisons of primary data from two of
these studies revealed poor correlation of individual gene
expression levels when the two distinct microarray platforms
were compared. They attributed the discordance to probe-
specific factors and expressed pessimism about the prospects
of comparing data across platforms. However, greater con-
cordance was observed when comparisons were restricted to
the subset of genes (generally < 25%) for which there was a
high confidence level of identity between the two array plat-
forms [16], or when analyses focused on gene sets sharing
similar biologic function or other attributes [17].
We used EXALT to compare expression signatures obtained
from analysis of NCI-60 expression data representing nine
different cancers (breast, colon, prostate, central nervous sys-
tem, leukemia, melanoma, lung, renal, and ovarian; Table 2).
Expression data from individual cell lines derived from the
same cancer type were assumed to represent biologic repli-
cates that were more similar within a group than between dif-
ferent groups. We deduced expression signatures from each
study, then added these signatures (n = 89) to SigDB to ena-
ble EXALT analysis (Table 2). Next, we used the expression
signatures as queries to search SigDB, and then ordered the
results based on adjusted mean P value corresponding to each
query dataset. The primary goal of these comparisons was to
determine whether similarities of expression signatures
among biologically related datasets could be detected across
different microarray platforms.
Figure 3 illustrates the significance levels for EXALT analyses
organized by query dataset. The most significant match for
each comparison was a self-match, and the next most closely
related signatures were between studies that used the
Affymetrix platform (query datasets A and B; Figure 3). Inter-
estingly, EXALT also detected GDS89, an updated full ver-
sion of dataset C generated by the same research group using
spotted cDNA arrays. To test whether other NCI-60 data were
present that were not identified by EXALT, we searched the
original GEO database (May 2006 release) using various key
words, including 'NCI60', and only one additional dataset
(GDS88) was identified. GDS88 consisted of four groups
representing four different cancer types, but three out of four
cancer types had only one sample. Therefore, the experimen-
tal design in this dataset could not be used by EXALT to
define signatures, and this explains why no match was found
to GDS88 in the initial search. Although the greatest signifi-
cance levels were observed in self-matching datasets and
between expression data obtained using the same microarray
platform, there was also statistical confidence across plat-
forms for these biologically related data sets (datasets B and
C). These findings demonstrate that EXALT can infer biologic
relationships between datasets generated using different
array platforms.
Use of EXALT in meta-analysis
Meta-analysis has been demonstrated to provide a strategy
for exploiting comparable microarray data from multiple
sources to validate observations made by a single study [18].
We tested whether EXALT could enable meta-analysis of
microarray data for the purpose of result validation in the set-
ting of cancer gene expression, specifically breast cancer.
We selected a query dataset derived from a published study
that examined gene expression differences among 69 estro-
gen receptor (ER)-negative and 226 ER-positive tumors
using inkjet-synthesized oligonucleotide microarrays [19].
The comparison between ER-positive and ER-negative sam-
Significance trends among matching datasets Figure 2
Significance trends among matching datasets. Six representative query 
datasets from the 124 self-matching results were compared using EXALT 
with all Gene Expression Omnibus (GEO) records. Corresponding 
adjusted mean P values for each dataset match are plotted on a log10 scale. 
The match number reflects the rank order of adjusted mean P values for 
each query dataset with one representing the best match. Self-matches 
exhibited the lowest adjusted mean P value for all query datasets and were 
ranked 1 in each search. EXALT, EXpression signature AnaLysis Tool; 
GDS, GEO dataset.
Match number Query
P valueR133.6 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. http://genomebiology.com/2007/8/7/R133
Genome Biology 2007, 8:R133
ple groups enabled EXALT to extract one gene expression sig-
nature. Using EXALT to search SigDB, we identified a single
matching subject dataset (GDS1329; adjusted mean P value =
0.0002) obtained from a study using Affymetrix HG-U133A
arrays. Interestingly, GDS1329 involved an analysis of 49
b r e a s t  c a n c e r  t u m o r s  c l a s s i f i e d  i n t o  l u m i n a l ,  b a s a l ,  a n d  a
novel apocrine cell type [20]. Importantly, luminal tumors
are typically ER-positive, whereas basal tumors are ER-nega-
tive. Three signatures were generated from this study design,
and the query signature had a significant and specific match
to one of the three. The matching subject signature was
derived from a specific comparison between 16 basal ER-neg-
ative tumor samples and 27 luminal ER-positive samples.
This finding suggests that EXALT successfully validated
breast cancer ER-negative versus ER-positive gene expres-
sion signatures by comparing two datasets generated by inde-
pendent groups using different microarray platforms. This
result also illustrates how EXALT can be used to identify bio-
logically related datasets on the basis of inherent properties of
gene expression signatures.
The use of expression profiles as biomarkers to predict dis-
ease prognosis and outcome has become an important
adjunct diagnostic tool in cancer [21,22]. However, both
training and testing datasets in such predication models typ-
ically originate from the same dataset or study. Using an in
silico validation strategy, such as we have illustrated here
with EXALT, the confidence level in identifying predictive
signatures could potentially be increased without performing
additional experiments.
Other tools for meta-analysis of microarray data
There are many obstacles to the sharing and widespread use
of microarray data. In general, expression measurements
made across microarray technologies are not directly compa-
rable [15,23]. Microarray data are inherently more complex
than other biologic data types, and there are no universal
standards or comparable measurement units. Comparisons
among datasets have been particularly difficult [24], as evi-
denced by the poor correlation between cDNA and oligonu-
cleotide arrays [15,25]. Further advances in genomics and
systems biology will require new analysis paradigms that are
capable of performing comparisons among experiments that
are platform independent.
Previously proposed strategies for comparing multiple micro-
array datasets can be broadly considered in two categories:
direct comparisons of significant gene lists, and indirect com-
parisons based on gene ontology or other shared biologic
knowledge. The most simple direct comparison strategy
involves comparing lists of significant genes among related
studies and visualizing overlapping genes using Venn dia-
grams or other methods. Automated versions of this
approach such as L2L [26] and LOLA [27], provide quick
methods with which to compare lists, but they are quite lim-
ited by database scale and the reliance upon potentially heter-
ogeneous analysis strategies used by the original studies from
which the lists are generated.
A more advanced comparison strategy of significant gene lists
is provided by Oncomine [18], a comprehensive and expertly
annotated database of gene expression studies related to can-
Table 2
Datasets from gene expression studies of the NCI-60 cell lines
Dataset name Array type Total clones Cancer classes Signature number
Stanford_Brown_NatGenetV24P227 cDNA 9,706 9 36
Harvard_Kohane_PNASV97P12182 Affy 7,245 9 30
MIT_Golub_PNASV98P10787 Affy 6,810 9 23
Cross-platform dataset matching revealed by EXALT Figure 3
Cross-platform dataset matching revealed by EXALT. Heat-map 
illustrating the statistical significance among NCI-60 gene expression 
profiling experiments. The datasets include those reported by Staunton 
and coworkers [13] (dataset A), Butte and colleagues [12] (dataset B), 
Ross and coworkers [14] (dataset C), and GDS89. Datasets A and B were 
generated using Affymetrix arrays, whereas datasets C and GDS89 were 
generated using spotted cDNA arrays. Dataset comparisons exhibited 
adjusted mean P values below 0.01 (corresponding to values > 2.0 on the -
log10 scale). The greatest significance levels were observed for self-
matching and matches between studies using the same microarray 
platform. EXALT, EXpression signature AnaLysis Tool; GDS, Gene 
Expression Omnibus dataset.
0.6                                                6.2
A            B            C
Query dataset
A
B
C
GDS89
D
a
t
a
s
e
t
 
m
a
t
c
h
P value (-log 10) scalehttp://genomebiology.com/2007/8/7/R133 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. R133.7
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R133
cer. This analytical tool enables searches to identify cancer-
related expression data that demonstrate significant differen-
tial expression of a single gene of interest or a list of signifi-
cant genes related to a specific cancer type. Differential
expression data are pre-computed in Oncomine using a uni-
form statistical algorithm, and the developers of this system
have demonstrated success in performing comparative meta-
profiling to identify shared gene expression signatures across
several experiments, although this feature does not appear
accessible to the casual user. This system is limited to cancer-
related gene expression studies. Another described approach
to cross-platform analysis of microarray data, referred to as
'second order analysis', has been applied to deduce networks
of transcription factors in yeast [28]. In this approach, the
expression patterns of co-expressed gene pairs or 'doublets'
were examined across multiple datasets to infer functional
linkages (first order analysis). Then, groups of doublets are
clustered together based on similar patterns of co-expression.
Although capable of elucidating hidden functional linkages
among genes, utilization of this method requires substantial
informatics expertise.
Recently, Lamb and coworkers [29] described a microrray
database search algorithm in an application called the Con-
nectivity Map (CMAP). Like EXALT, CMAP performs micro-
array signature based comparisons, but the two strategies
have several important distinctions. At the database level,
CMAP has a focused goal to profile drug-related cancer signa-
tures in ten cell lines, and therefore only a small number of
signatures (564) were generated. By contrast, SigDB used by
EXALT included 16,181 signatures, representing hundreds of
different experimental types from many different tissues. All
collected subject signatures in CMAP were derived from one
laboratory using a single microarray platform, and signatures
derived from other platforms were not demonstrated to work
with CMAP. Again, by contrast, SigDB contained data gener-
ated with multiple platforms that are fully accessible by
EXALT. Other differences include the lack of a unified
method for query signature production in CMAP and restric-
tions on signature length (1,000 genes), whereas EXALT has
stringent requirements for query signatures and no limit to
the number of genes in a signature (average signature length
in SigDB is 1,683 genes). Finally, even though both strategies
use signed rank genes as the basis for signatures from a two-
group comparison, CMAP does not require biologic replicates
in a sample group and no statistical confidence is assigned to
each ranked gene, as is done by EXALT.
Unique features and limitations of EXALT
We developed EXALT to assist researchers wishing to com-
pare the results of multiple gene expression profiling experi-
ments. A key feature of our approach is that it enables
comparative analysis of microarray datasets based on signa-
ture similarity. A second important attribute is the use of a
large, standardized database of microarray data (GEO) and
the ability to incorporate virtually any publicly accessible data
source. We further implemented an algorithm for performing
comprehensive signature comparisons and a user friendly
report format. These features provide a potential platform for
sharing and comparing all microarray data in a manner suit-
able for widespread use.
The encoded signatures used by EXALT can serve as unique
identifiers for the datasets from which they are derived. Com-
monly used microarray data analysis methods identify a small
fraction of all data based on statistical differences in gene
expression. EXALT follows the same principle to extract sig-
nificant genes from pre-processed microarray datasets, but it
further compiles these data into a searchable format. This
abstraction process reduces the total amount of data by more
than 1,000-fold and allows for a more efficient and accurate
search. More importantly, the nonparametric reduction in
the volume of data achieves the goal of making different
microarray expression datasets comparable. Even though the
extracted signatures represent only 10% of the original data
records, our results of self-matching (Table 1) indicate that
they are unique and sensitive enough to identify original data-
sets through signature comparisons.
EXALT, like all other methods for analyzing microarray data,
has defined limitations. Signatures were not always extracta-
ble from microarray datasets. Some GEO records did not have
sufficient information to evaluate statistically. Similar to the
GEO analysis tool and Oncomine, EXALT uses a single signif-
icance test (t-test) to extract signatures from all experimental
designs, and significant genes were defined based on a two-
group comparison strategy. No signature could be produced
if a comparison between two groups was not statistically sig-
nificant. Our method adheres strictly to the group design
specified by the investigators, and additional novel compari-
sons within a dataset are not enabled. Signatures resulting
from multiple group comparisons in the original dataset (for
instance, time series experiments) could not be analyzed
because the current GEO data structure does not provide a
computable attribute to identify this type of experiment or
hypothesis. However, other statistical comparison methods
in conjunction with additional user controls are being consid-
ered for future implementations of EXALT. Transcripts
(expressed sequence tags) that have not been assigned to
known genes having valid RefSeq identifiers cannot be
included in signatures, and this will be a limitation until gene
nomenclature becomes universally comprehensive and
standardized.
Potential applications of EXALT
There are many potential applications of global microarray
data comparisons using EXALT. For example, investigators
can gain significant increases in the power of detecting differ-
entially expressed genes [30] through in silico validation and
comparisons with homologous microarray datasets. EXALTR133.8 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. http://genomebiology.com/2007/8/7/R133
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can also enable large-scale searches for 'modules' of signa-
tures with coordinated transcription across a wide range of
conditions in three distinct species. Drug discovery is another
area driving interest in comparing microarray datasets. Ther-
apeutic effects and toxicity of new drugs could be investigated
by correlating gene expression signatures associated with
known drug or toxic responses [23,31,32]. Finally, enabling
widespread use and comparisons of microarray data will
enhance the value of public repositories such as GEO and
stimulate other innovative approaches to exploiting these
data.
Materials and methods
Data collection
We collected publicly available gene expression data from
several sources. Our primary source of preprocessed micro-
array data sets was the GEO [33]. We used the May 2006
release of GEO. The logically related samples from the exper-
iments represented by these records define GEO series
records. About one-third of GEO series records have passed
GEO internal control processes and are designated as GEO
Data Sets (GDSs). GDS records are curated sets of gene
expression measurements with processes such as background
correction and normalization that are consistent across data-
sets [3]. A GDS record represents a collection of biologically
and statistically comparable GEO samples that can be exam-
ined using the GEO suite of data display and analysis tools.
Other datasets, as described below, were downloaded from
publicly accessible sites named by the following conventions:
company or institution; last name of corresponding author or
dataset name; and journal abbreviation, volume (starting
with 'V'), and starting page number (starting with 'P').
The NCI-60 datasets were derived from 60 human cancer cell
lines and used by the US National Cancer Institute to screen
for new antineoplastic drugs [15,16]. The NCI-60 panel used
in this study included cell lines derived from breast, colon,
prostate, and central nervous system cancers, and leukemia.
The NCI-60 cell lines had been profiled using cDNA micorar-
rays (Stanford_Brown_NatGenetV24P227) [14], and
Affymetrix oligonucleotide HU6800 microarrays
(Harvard_Kohane_ PNASV97P12182 and
MIT_Golub_PNASV98P10787) [12,13]. Additional informa-
tion is provided in Table 2.
Extracting gene expression signatures
We developed a four-step process to extract gene expression
signatures from a dataset. First, data were formatted, if nec-
essary, to a common data type, namely the SOFT format used
by GEO. Reformatting included a minor reconfiguration of
data annotation. All gene probe identifiers were translated to
the corresponding NCBI Reference Sequence identifiers (Ref-
Seq ID) [34] using our previously described Gene Annotation
Project (GAP) database [35]. The RefSeq collection provides
a comprehensive, integrated, nonredundant set of gene iden-
tifiers. Furthermore, RefSeq IDs are more stable and reliable
than UniGene clusters [36]. Second, for every two groups of
samples in a dataset, we generated an expression signature.
Following file conversion, each gene was assessed for the sig-
nificance of differential expression using a two-sided Stu-
dent's t-test. When multiple probes have the same RefSeq
identifier, we analyzed them separately through the statistical
testing step and then grouped them into a single record hav-
ing a mean P value derived from the individual probes. To
account for multiple hypothesis testing, P values determined
for each significant gene were further adjusted by the false
discovery rate (FDR) method using Q values [37]. Third, a list
of significant genes with Q value of 0.2 or less was generated.
For each significant gene, a Q score was calculated as the log-
arithm of reciprocal Q value (-log [Q value]). Finally, a gene
expression signature was generated as a list of 'triplets', each
defined as RefSeq ID - direction code - Q score. The direction
code is defined by the relative difference between two group
means and can have one of three values (U [up], D [down], or
X [uncertain]). The order of the two groups is arbitrary, and
so the direction code will be reversed if the group order is
flipped. However, the approach used to perform signature
comparisons (see below) is not affected by the order of groups
assigned at the time when signatures were extracted. Signa-
tures were stored in a flat file database (SigDB).
Queries to our system are facilitated through a web-based
computational pipeline (AESP) to automate the extraction of
gene expression signatures from microarray datasets [5].
Input information includes dataset name, sample number,
sample names, microarray platform, and group assignments.
AESP performs translation of probe IDs, significance tests,
and the encoding of gene expression signatures for use by
EXALT. A unique dataset trackin g  I D  i s  a s s i g n e d  t o  e a c h
input query dataset that can be used later to retrieve an
EXALT report.
The EXALT server was implemented on a high throughput
multi-CPU Linux cluster using PERL and system scripts. The
primary platform was the Vanderbilt University Advanced
Computing Center for Research & Education (ACCRE), which
currently consists of 1,302 processors in 651 nodes, each with
at least 1 gigabyte of memory, and dual gigabit ethernet ports.
Processing all available GDS records (874 records, approxi-
mately 2 gigabytes in size) from 14,303 hybridizations on a
35-CPU ACCRE subcluster required an average of 72 hours
CPU time. A typical query dataset contains three groups. It
can generate three signatures, with about 1,000 signature
genes per signature. A typical EXALT analysis (for instance,
production of signatures and then comparison with SigDB)
will take approximately 2 hours on a single CPU.
Comparison of gene expression signatures
In an EXALT analysis, each query signature was compared
with every subject signature in SigDB. For each pair of query
and subject signatures with lengths Lq and Ls , a total identityhttp://genomebiology.com/2007/8/7/R133 Genome Biology 2007,     Volume 8, Issue 7, Article R133       Yi et al. R133.9
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score (TIS) was computed in three steps. First, the signatures
were aligned by matching RefSeq ID, then the direction codes
(U, D, or X) for matching genes were determined to be con-
cordant (U-U or D-D), discordant (U-D), or uncertain (direc-
tion code X in either query or subject). Next, the Q scores
were summed separately for concordant and discordant
matches to give a positive identity score (PIS) and a negative
identity score (NIS), respectively, using the following
equations:
Where N and M are numbers of concordant and discordant
matches, respectively, and Siq and Sis (Sjq and Sjs ) are Q scores
for the i-th concordant (j-th discordant) match in the query
and subject signatures. The NIS score was assigned a negative
value because of its opposite direction from PIS scores.
Matches with at least one direction code of X and all non-
matching genes were excluded from the identity score calcu-
lations. Finally, the TIS was computed as the absolute value of
the sum of PIS and NIS divided by the sum of signature
lengths (Lq + Ls ) using the following: TIS = |PIS + NIS|/(Lq +
Ls ).
Defining significance level
We carried out simulations to determine the statistical signif-
icance of TIS values. We generated 1,000 random query sig-
natures and computed TIS between each query signature and
each subject signature in SigDB. The random query signa-
tures had similar properties (length distribution, RefSeq ID
frequency, and uniqueness) as compared with those of the
actual data. The results suggested that TIS score correlated
with query signature length. To adjust for the influence of
query signature length, we derived the mean and standard
deviation (SD) of TIS as functions of query length and then
normalized TIS by converting to Z score using the following
equation: ZTIS score = (TIS - mean)/SD, where mean and SD
are functions of query length. This enabled us to generate an
empirical distribution of ZTIS scores. For a real query, we fol-
lowed the same procedure to calculate the ZTIS score, and
compared it with the empirical distribution to estimate corre-
sponding query P value. A query is statistically significant if
its P value is 0.01 or less.
Reporting EXALT results
An algorithm for reporting EXALT results was implemented
that considers information at three different levels: dataset,
individual expression signature, and significant genes within
a signature. The gene-level report contains alignments of sig-
nificant gene triplets that were matched from within a pair of
query and subject signatures. The signature level report con-
tains matches between whole expression signatures. A query
signature may have none to many significant matches or 'hits'
in a subject signature in SigDB, and the match with the small-
est query P value is designated as the 'top hit'.
The most global comparison is a dataset (top-level) report,
which describes the similarity between a query dataset and a
dataset in SigDB. For this, a query dataset may have one or
more query signatures, and each query signature may match
one top hit in each subject dataset. The most similar dataset
is selected based on two criteria. The first criterion is the aver-
age of query P values from all top hit signatures divided by the
total number of top hits (TS). The second criterion is the top
hit ratio calculated as the total number of top hits divided by
the total number of query signatures (TQ). An adjusted mean
P value is calculated by an arithmetic average of all top hit
query P values divided by the top hit ratio, and this is used to
rank the confidence levels of data set matches.
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